Pulmonary Fibrotic Diseases This review covers fibrotic pulmonary diseases. Although
idiopathic pulmonary fibrosis is very common, the review focuses mainly on fibrotic diseases …

Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ
involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous …

Objective Tocilizumab (TCZ) has demonstrated lung function preservation in 2 randomized
controlled trials in early systemic sclerosis (SSc). This effect has yet to be characterized in …

CXCL13 is a B-cell chemokine produced mainly by mesenchymal lymphoid tissue organizer
cells, follicular dendritic cells, and human T follicular helper cells. By binding to its receptor …

Our previous study demonstrated increased expression of Heat shock protein (Hsp) 90 in
the skin of patients with systemic sclerosis (SSc). We aimed to evaluate plasma Hsp90 in …

Single-cell RNA sequencing (scRNA-seq) has revolutionized transcriptomic studies by
providing unprecedented cellular and molecular throughputs, but spatial information of …

Janus kinase (JAK) inhibitors (also termed Jakinibs) constitute a family of small drugs that
target various isoforms of JAKs (JAK1, JAK2, JAK3 and/or tyrosine kinase 2 (Tyk2)). They …

Connective tissue disease (CTD) related interstitial lung disease (CTD-ILD) is one of the
leading causes of morbidity and mortality of CTD. Clinically, CTD-ILD is highly heterogenous …

Abstract Background Systemic sclerosis (SSc) is a systemic autoimmune disease with
heterogeneous clinical presentation and prognosis. JAK inhibitors reduced cutaneous and …

Background Interstitial lung disease (ILD) is the most common cause of death in systemic
sclerosis. To date, the progression of systemic sclerosis-associated ILD is judged by the …